- Home
- GXO vs LEGN Comparison
GXO vs LEGN Comparison
Compare GXO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXO
- LEGN
- Stock Information
- Founded
- GXO 2021
- LEGN 2014
- Country
- GXO United States
- LEGN United States
- Employees
- GXO N/A
- LEGN N/A
- Industry
- GXO Transportation Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- GXO Consumer Discretionary
- LEGN Health Care
- Exchange
- GXO Nasdaq
- LEGN Nasdaq
- Market Cap
- GXO 5.9B
- LEGN 6.0B
- IPO Year
- GXO N/A
- LEGN 2020
- Fundamental
- Price
- GXO $45.25
- LEGN $34.67
- Analyst Decision
- GXO Buy
- LEGN Strong Buy
- Analyst Count
- GXO 13
- LEGN 13
- Target Price
- GXO $65.38
- LEGN $80.62
- AVG Volume (30 Days)
- GXO 1.5M
- LEGN 1.3M
- Earning Date
- GXO 02-11-2025
- LEGN 03-10-2025
- Dividend Yield
- GXO N/A
- LEGN N/A
- EPS Growth
- GXO N/A
- LEGN N/A
- EPS
- GXO 0.89
- LEGN N/A
- Revenue
- GXO $11,049,000,000.00
- LEGN $520,183,000.00
- Revenue This Year
- GXO $20.79
- LEGN $121.04
- Revenue Next Year
- GXO $10.10
- LEGN $67.39
- P/E Ratio
- GXO $50.84
- LEGN N/A
- Revenue Growth
- GXO 14.44
- LEGN 122.96
- 52 Week Low
- GXO $41.38
- LEGN $30.17
- 52 Week High
- GXO $63.33
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- GXO 46.47
- LEGN 50.64
- Support Level
- GXO $43.95
- LEGN $30.17
- Resistance Level
- GXO $45.38
- LEGN $37.92
- Average True Range (ATR)
- GXO 1.14
- LEGN 2.19
- MACD
- GXO 0.64
- LEGN 0.31
- Stochastic Oscillator
- GXO 91.38
- LEGN 58.06
About GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.